Advaxis — Investor Presentation (October 2019)
28 slides from Advaxis's investor presentation, Oct 4, 2019
Slide 1: Advaxis Corporate Presentation
ADVAXIS Corporate Presentation Nasdaq: ADXS October 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The fa
Slide 3: Corporate Overview
Corporate Overview Corporate Facts * Founded 2002; HQ in Princeton, NJ « ~40 employees ¢ Recently financed raising $17 million ¢ 48 million shares outstanding as of September 30, 2019 Platform Technology * Clinically validated, unique immuno-oncology platform ¢ Bacterial vector equipped with targete
Slide 4: Investment Highlights
Investment Highlights Validated and Versatile I/O Platform Innovative Platform Immunogenicity and Clinical Signals + Proprietary bacterial vector/platform can : elicit rapid and strong immunological activity + Nearly 500 patients treated, manageable yy safety profile") NEO: 90% CD8+ T cell reactivit
Slide 5: Clinical Pipeline
Clinical Pipeline ine Cancer In Co ee ADXS - NEO NSCLC, MSS-CRC, Head & Neck, Melanoma, Bladder ADXS - HOT Non-Small Cell Lung Prostate 3& IND Submission 2H 2019 Bladder 3& IND Submission 1H 2020 ADXS - HPV (AXAL) HP\V+ Head and Neck (Partners to be announced) e018 ADXS - PSA Metastatic Prostate in
Slide 6: Lm Platform Technology
Lm Platform Technology Proprietary Antigen Delivery Platform that Activates the Immune System, Naturally
Slide 7: Lm Platform Designed to Trigger Strong Immune Responses with Targeted Antigens
Lm Platform Designed to Trigger Strong Immune Responses with Targeted Antigens Three Core Components Comprehensive Immune Activity ¢ Listeria monocytogenes (Lm) bacteria Attenuated Lm = Carrier vector; irreversibly attenuated() = Mimic infection and redirect immune response against Carrier Vector |
Slide 8: Using the Body's Own Immune System to Fight Cancer
Using the Body’s Own Immune System to Fight Cancer Harnessing the Unique Life Cycle of Lm in APCs => ye ) Live attenuated strains Upon infusion, Target peptides Activated CD8+ T of Lm are Bioengineered Lm are presented on APC cells seek out and kill bioengineered to phagocytosed by surface stimulate
Slide 9: Advaxis Technology Evolution: Higher Payloads, New Targets
Advaxis Technology Evolution: Higher Payloads, New Targets ADXS-HPV (AXAL) Prolonged survival and complete responses in cervical and anal cancer patients and antigen spreading observed Single antigen delivery platform ADXS-PSA In combination with KEYTRUDA® prolonged survival in metastatic castration
Slide 10: ADXS-NEO
10 ADXS-NEO Our Personalized Neoantigen-Directed Therapy In Phase 1 for Non-Small Cell Lung, MSS-Colorectal, Head & Neck, Melanoma and Bladder Cancers
Slide 11: Neoantigen-Directed Immunotherapies Can Transform Cancer Treatment
Neoantigen-Directed Immunotherapies Can Transform Cancer Treatment ¢ |/O treatments work to harness the power of individuals’ immune system Without with UJ Without with Immunotherapy | immunotherapy Immunotherapy | Immunotherapy ¢ Immune Checkpoint Inhibitors (ICls) have dramatically altered the can
Slide 12: Unlocking the Potential of Neoantigens
Unlocking the Potential of Neoantigens « Neoantigens are only found in cancer cells - making them good targets for therapies * T cells that target neoantigens are the common link among successful immunotherapies developed to date (e.g., checkpoint inhibitors, Tumor Infiltrating Lymphocytes or TILs)
Slide 13: Lm Technology: Overcoming Challenges in the Neoantigen Landscape
Lm Technology: Overcoming Challenges in the Neoantigen Landscape Hurdles and shortcomings Lm Technology™ potential advantages Limited clinical evidence « ~500 patients treated Low immune response No demonstrated effect on total mesorectal excision Strong immunologic activity in the clinic Clinical e
Slide 14: NEO Manufacturing and Trial Design
° ° ° NEO Manufacturing and Trial Design Title: A Phase 1 Dose-Escalation Study of ADXS NEO Expressing Personalized Tumor Antigens, Alone Identify Patient's Neoepitopes and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Solid Tumors Sequencing Neoantigen prioritization Tri
Slide 15: Early Data From ADXS-NEO Program
Early Data From ADXS-NEO’' Program ¢ Emerging data suggest potential for rapid, strong and broad CD8* T cell response to targeted neoantigens = 100% patients (n=3) had CD8* T cell responses to at least 1 peptide within 1 week after first dose = CD8* T cells generated against 90% of peptides in first
Slide 16: Strong Competitive Position within Neoantigen Landscape
Strong Competitive Position within Neoantigen Landscape T cell Generation Demonstration of % CD8+ IVS Assay (In- Vitro Stimulation, Capacity Antigen Spreading Against Hotspot Clinical Impact in Late- Central memory) Mutations Stage Setting Peer Data? 47% 33% 10-30 Unknown. Unknown. Most studies done
Slide 17: ADXS-HOT
ADXS-HOT Off-the-Shelf Hotspot Neoantigen-Directed) Therapy Phase 1/2 in Non-Small Cell Lung Cancer 17
Slide 18: ADXS-HOT
ADXS-HOT Targeting Multiple Hotspots, OFAs and CTAs Increases Patient Applicability and Clinical Activity Potential Hotspot mutations have demonstrated pre-clinical activity in Advaxis’ Lm Technology’ Data on fle, Adv: ADXS-HOT constructs target both public, or shared, hotspot neoantigens and multip
Slide 19: HOT Development Overview — Lung Phase 1/2 Clinical Trial
HOT Development Overview — Lung Phase 1/2 Clinical Trial ClinicalTrials.gov Identifier: NCT03847519 Title: A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination with Pembrolizumab in fights | Subjects with Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer * PartAin monother
Slide 20: ADXS-PSA
ADXS-PSA Prostate Cancer Therapy
Slide 21: PSA Development Overview — Phase 1-2 Clinical Trial
PSA Development Overview — Phase 1-2 Clinical Trial ClinicalTrials.gov Identifier: NCT02325557 Title: A Phase 1/2 Dose-Escalation and Safety Study of ADXS31-142 Alone and in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Trial desig
Slide 22: Clinical History
Clinical History Demonstration of Safety and Efficacy
Slide 23: Lm Safety
Lm Safety Summary of ADXS-HPV (AXAL) Treatment-Related Adverse Events Treatment-Related Adverse Events Reported >5% with ADXS11-001 (AXAL) Monotherapy: n (%) Adverse Events (N=192) Preferred Term Chills Pyrexia Nausea Vomiting Hypotension Headache Tachycardia Cytokine release syndrome Gamma-glutamyi
Slide 24: HPV Scientific Summary
HPV Scientific Summary Extensive Clinical Experience with Demonstrated Clinical Benefit [rhase Cancer| seting) Line | ncT [IT | combo. | stat Jon Dus] statue] 38% 12-month survival rate (19/50) cc. HRLA Adjuvant after NCT 7 7 Sep TaRLate aan + Highest 12m OS rate achieved to-date at GOG AUSIEE LATED
Slide 25: Key Financial Information
Key Financial Information Cash, Cash Equivalents and Marketable Securities, as of July 31, 2019 $41.8MM Shares Outstanding, as of September 30, 2019 48.0MM Fully Diluted Shares Outstanding, as of September 30, 2019 51.0MM Research and Development Expenses $19.7MM General and Administrative Expenses
Slide 26: Anticipated Catalysts Over the Next Months
Anticipated Catalysts Over the Next 12 Months PROGRAM COMPLETED/ANTICIPATED MILE: NES + Metastatic Prostate Ph1/2 Combination with pembrolizumab--Part B Combination ADXS-PSA Therapy Data (updated survival and preliminary biomarker data) presented at AACR Q12019* + Updated survival data from Part B 2
Slide 27: Advaxis Management
Advaxis Management Seasoned Management Team Transaction Oriented Chief Executive Officer Chief Financial Officer Chief Medical Officer Head of Scientific Advisory Board Kenneth A. Berlin Molly Dr. Andres Henderson Gutierrez ROSETTAGENOMICS™ TOVANCE Onxcerrres @ Brisoh Myers pera iewaen Wurruascones
Slide 28: Thank You
Thank You